Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4757991 | 0.86 | CA12 (0.65) | USP2SIGMAR1ALDH1A1CA12CA2 | |
| SCHEMBL4068121 | 0.83 | LMNA (0.50) | ALDH1A1MAPK1CA12CA2CA9 | |
| SCHEMBL3322300 | 0.79 | USP2 (0.70) | USP2SIGMAR1ALDH1A1MAPK1GFER | |
| SCHEMBL9492210 | 0.79 | USP2 (0.70) | USP2SIGMAR1ALDH1A1MAPK1GFER | |
| SCHEMBL16359721 | 0.79 | USP2 (0.69) | USP2SIGMAR1ALDH1A1MAPK1GFER | |
| SCHEMBL4075458 | 0.78 | ALDH1A1 (0.58) | ALDH1A1MAPK1CA12CA2CA9 | |
| SCHEMBL6295282 | 0.76 | USP2 (0.66) | USP2SIGMAR1ALDH1A1MAPK1GFER | |
| SCHEMBL13901771 | 0.76 | CYP3A4 (0.42) | ALDH1A1CA12CA2CA9SMN1; SMN2 | |
| SCHEMBL7042796 | 0.76 | USP2 (0.65) | USP2SIGMAR1ALDH1A1MAPK1GFER | |
| SCHEMBL3322296 | 0.76 | USP2 (0.61) | USP2SIGMAR1ALDH1A1MAPK1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470698-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070249641-A1 | ADENOSINE A3 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2007-10-25 | — | — | US | disclosed |
| US-7271171-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060040959-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-02-23 | — | — | US | disclosed |
| EP-1499614-A4 | ADENOSINE A3 RECEPTOR MODULATORS | KING PHARMACEUTICALS RES & DEV (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6921825-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICUALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1499614-A1 | ADENOSINE A3 RECEPTOR MODULATORS | King Pharmaceuticals Research and Development Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003095457-A1 | ADENOSINE A3 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| US-20030144266-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040959-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | USP2 4407/4885SIGMAR1 550/4885ALDH1A1 549/4885 |
| US-20070249641-A1 | ADENOSINE A3 RECEPTOR MODULATORS | ADORA3, ADORA2A, ADORA1 | USP2 4407/4885SIGMAR1 550/4885ALDH1A1 549/4885 |
| US-20030144266-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | USP2 4295/4885SIGMAR1 432/4885ALDH1A1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.